Skip to content
Open access

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

Aug 2026 · Nature Medicine · 0 citations · 22 references
Medicine

TL;DR

A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.

Abstract

Among the most commonly cited reasons for failure to initiate comprehensive medical therapy in patients with heart failure are concerns relating to hypotension, kidney dysfunction and hyperkalemia. Here we performed a pooled individual participant-level analysis and developed a prediction model to estimate the short-term (2-12 weeks) treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium. A total of 38,753 participants (16,877 with heart failure with reduced ejection fraction (HFrEF) and 21,876 with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF)) across nine randomized trials were included in the analysis, which tested angiotensin receptor blocker-neprilysin inhibitor (ARNI), steroidal mineralocorticoid receptor antagonist (sMRA), nonsteroidal MRA (nsMRA) and sodium glucose cotransporter-2 inhibitors (SGLT2i). For HFrEF, the estimated mean (95% prediction intervals (PIs)) treatment effect on SBP with combination ARNI + SGLT2i + sMRA therapy was -9.2 (-10.6 to -7.8) mmHg. For HFmrEF/HFpEF, the estimated mean (95% PI) treatment effects on SBP with SGLT2i + sMRA therapy and with SGLT2i + nsMRA therapy were -5.9 (-7.3, -4.6) and -4.8 (-5.7, -4.0) mmHg, respectively. For HFrEF, the estimated treatment effects of ARNI + SGLT2i + sMRA on eGFR and serum potassium were -6.8 (-7.9, -5.4) ml min-1 m-2 and +0.30 (0.25, 0.35) mmol l-1, respectively. For HFmrEF/HFpEF, the treatment effects for combination SGLT2i + sMRA and SGLT2i + nsMRA on eGFR were -7.7 (-8.9, -6.4) and -6.1 (-6.7, -5.5) ml min-1 m-2, respectively and for serum potassium were +0.34 (0.29, 0.38) and +0.21 (0.18, 0.25) mmol l-1, respectively. These analyses provide individualized estimates of the expected treatment effect for any combination of medical therapies in HFrEF and HFmrEF/HFpEF on BP, kidney function and serum potassium.

Read PDF

Similar papers

Review Open access Aug 2026

Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction

Overall, using a combination of these newer treatments may help people with heart failure whose heart still pumps normally or nearly normally feel better, improve their quality of life, and achieve better long-term health outcomes.

Craig J. Beavers, S. Greene · 0 citations
Open access Sep 2026

Eficacy of Dapagliflozin in Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial Study

Heart failure (HF) with preserved ejection fraction (HFpEF) is a major clinical difficulty caused by the existence of restricted therapeutic alternatives. Sodium-glucose cotransporter-2 inhibitors, including dapagliflozin, have demonstrated possible benefits in the therapy of HF. A randomized controlled...

Saurav P. Singhvi, V. Selvaraj, Naveena Dhandapani et al. · 0 citations
Open access Sep 2026

Impact of renin–angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation

ABSTRACT Background Renin–angiotensin system (RAS) inhibitors are a cornerstone of cardiovascular and kidney risk modification in chronic kidney disease (CKD). Yet, they are often discontinued in advanced CKD to limit adverse effects or to delay kidney replacement therapy (KRT). Methods From the CKD-Renal Epidemiology...

V. Maisons, M. Costes-Albrespic, Sophie Liabeuf et al. · 0 citations
Open access Aug 2026

Heart Failure With Reduced Ejection Fraction and SGLT2 Inhibitors- Clinical Outcomes, Adverse Events, and Comorbidities Over Three Years: A Retrospective Cohort Study

SGLT2 inhibitor use in heart failure with reduced ejection fraction was associated with significantly improved long-term survival and a substantial reduction in heart failure and acute coronary syndrome hospitalizations, without increased risk of AKI or UTI.

Jonathan Zawadzki, Ronit Kar, G. Bailey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.